Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026)
Champions Oncology's (CSBR) quarterly Asset Writedowns and Impairment came in at -$10000.0 in Q3 2026, up 65.52% year-over-year from -$6041.7 in Q3 2025, and down 113.51% on a QoQ basis from $74000.0 in Q2 2026.
Powered by 
Analysis
Champions Oncology (CSBR) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Champions Oncology (CSBR) has 8 years of Asset Writedowns and Impairment data on file, last reported at -$10000.0 in Q3 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 65.52% year-over-year to -$10000.0 in Q3 2026; TTM through Jul 2026 was $47000.0, a 120.43% increase from a year earlier, with the FY2026 full-year figure at $28000.0, up 110.29% from the prior year.
- Asset Writedowns and Impairment for Q3 2026 stood at -$10000.0, down from $74000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $724000.0 in Q2 2023 and bottomed at -$209000.0 in Q4 2024.
- Historically, Asset Writedowns and Impairment has averaged $64312.5 across 5 years, with a median of $30500.0 in 2025.
- The largest YoY upside for Asset Writedowns and Impairment was 270.21% in 2024 against a maximum downside of 390.28% in 2024.
- Year by year, Asset Writedowns and Impairment stood at $130000.0 in 2022, then tumbled by 44.62% to $72000.0 in 2023, then sank by 390.28% to -$209000.0 in 2024, then surged by 106.22% to $13000.0 in 2025, then plunged by 176.92% to -$10000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were -$10000.0 in Q3 2026, $74000.0 in Q2 2026, and -$30000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -10,000.00 |
| Apr 30, 2026 | 74,000.00 |
| Jan 31, 2026 | -30,000.00 |
| Oct 31, 2025 | 13,000.00 |
| Jul 31, 2025 | -29,000.00 |
| Apr 30, 2025 | 48,000.00 |
| Jan 31, 2025 | -40,000.00 |
| Oct 31, 2024 | -209,000.00 |
| Jul 31, 2024 | -71,000.00 |
| Apr 30, 2024 | 162,000.00 |
| Jan 31, 2024 | 80,000.00 |
| Oct 31, 2023 | 72,000.00 |
| Jul 31, 2023 | 162,000.00 |
| Apr 30, 2023 | 724,000.00 |
| Jan 31, 2023 | -47,000.00 |
| Oct 31, 2022 | 130,000.00 |
| Jul 31, 2017 | 14,000.00 |
| Apr 30, 2017 | 24,000.00 |
| Jan 31, 2017 | 2,000.00 |
| Jul 31, 2016 | -2,000.00 |